Influence of Statins on Perioperative Outcomes

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 20, Issue 2, 2006, Pages 251-258

  Hindler, Katja ^a   Eltzschig, Holger K ^b   Fox, Amanda A ^c   Body, Simon C ^c   Shernan, Stanton K ^c   Collard, Charles D ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cholesterol; HMG CoA reductase inhibitor; inflammation; prevention; surgery; transplantation

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARTMENT SYNDROME; CORONARY ARTERY BYPASS SURGERY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART INFARCTION; HEART SURGERY; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; LIVER TOXICITY; META ANALYSIS; MORBIDITY; MORTALITY; MUSCLE DISEASE; MYALGIA; MYOPATHY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PHARMACOGENETICS; PRIORITY JOURNAL; REPERFUSION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SLEEP DISORDER; SYSTEMATIC REVIEW;

CARDIOVASCULAR SURGICAL PROCEDURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 33645987310     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2005.12.012     Document Type: Review

References (104)

1. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes. A randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
2. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
3. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
5. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
6. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105 (2002) 691-696
7. Pan W., Pintar T., Anton J., et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110 (2004) II45-II49
8. Poldermans D., Bax J.J., Kertai M.D., et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107 (2003) 1848-1851
9. Dotani M.I., Elnicki D.M., Jain A.C., et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 86 (2000) 1128-1130
10. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336 (1997) 153-162
11. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin. A randomized trial. J Vasc Surg 39 (2004) 967-976
12. Abbruzzese T.A., Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 39 (2004) 1178-1185
13. Kertai M.D., Boersma E., Westerhout C.M., et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 116 (2004) 96-103
14. Antonini-Canterin F., Zuppiroli A., Popescu B.A., et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 92 (2003) 1479-1482
15. Collard C.D., Body S., Shernan S.K., et al. Preoperative statin therapy is associated with reduced cardiac mortality following coronary artery bypass graft surgery. Circulation 110 (2004) 504 (abstr)
16. Mangano D.T., Layug E.L., Wallace A., et al., Multicenter Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 335 (1996) 1713-1720
17. Endo A., and Hasumi K. Biochemical aspect of HMG CoA reductase inhibitors. Adv Enzyme Regul 28 (1989) 53-64
18. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
19. Dangas G., Smith D.A., Unger A.H., et al. Pravastatin. An antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 83 (2000) 688-692
20. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation 103 (2001) 926-933
21. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286 (2001) 64-70
22. Kinlay S., Schwartz G.G., Olsson A.G., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 (2003) 1560-1566
23. Brown W.V. Benefits of statin therapy in patients with special risks. Coronary bypass surgery, stable coronary disease, and acute coronary syndromes. Clin Cardiol 26 (2003) III13-III18
24. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
25. Chen J., Nagasawa Y., Zhu B.M., et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 93 (2003) 87-94
26. Lefer A.M., Campbell B., Shin Y.K., et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
27. Naidu B.V., Woolley S.M., Farivar A.S., et al. Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. J Thorac Cardiovasc Surg 126 (2003) 482-489
28. Wan M.X., Schramm R., Klintman D., et al. A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon. Br J Pharmacol 140 (2003) 395-401
29. Cipollone F., Fazia M., Iezzi A., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107 (2003) 1479-1485
30. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
31. Effect of simvastatin on coronary atheroma. The Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994) 633-638
32. Vaughan C.J., Gotto Jr. A.M., and Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35 (2000) 1-10
33. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
34. Hack C.E., and Zeerleder S. The endothelium in sepsis. Source of and a target for inflammation. Crit Care Med 29 (2001) S21-S27
35. Weber C., Erl W., Weber K.S., et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30 (1997) 1212-1217
36. Weitz-Schmidt G., Welzenbach K., Brinkmann V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
37. Lazar H.L., Bao Y., Zhang Y., et al. Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 125 (2003) 37-42
38. Dupuis J., Tardif J.C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
39. Laufs U., Gertz K., Huang P., et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31 (2000) 2442-2449
40. Xing Y., Chen H., and Hu D.Y. [Effects of withdrawal of statins on nitric oxide production in vascular endothelial cells]. Zhonghua Nei Ke Za Zhi 44 (2005) 22-24
41. Gertz K., Laufs U., Lindauer U., et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34 (2003) 551-557
42. Thomas M., and Mann J. Increased thrombotic vascular events after change of statin. Lancet 352 (1998) 1830-1831
43. Spencer F.A., Allegrone J., Goldberg R.J., et al. Association of statin therapy with outcomes of acute coronary syndromes. The GRACE study. Ann Intern Med 140 (2004) 857-866
44. Yildirir A., and Muderrisoglu H. Non-lipid effects of statins. Emerging new indications. Curr Vasc Pharmacol 2 (2004) 309-318
45. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
46. Turban S., Fuentes F., Ferlic L., et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154 (2001) 633-640
47. Marian A.J., Safavi F., Ferlic L., et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. The lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 35 (2000) 89-95
48. Vohl M.C., Szots F., Lelievre M., et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 160 (2002) 361-368
49. Kirchheiner J., Kudlicz D., Meisel C., et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 74 (2003) 186-194
50. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low-density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113 (1995) 157-166
51. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender-specific manner. Atherosclerosis 158 (2001) 183-193
52. Gerdes L.U., Gerdes C., Kervinen K., et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian simvastatin survival study. Circulation 101 (2000) 1366-1371
53. Olin J.W. Cholesterol lowering. Perspectives on the 4S and West of Scotland studies. Cleve Clin J Med 63 (1996) 80-83
54. Manzato E. Scandinavian simvastatin study (4S). Lancet 344 (1994) 1767
55. Wright R.A., and Flapan A.D. Scandinavian simvastatin study (4S). Lancet 344 (1994) 1765
56. Ahmed M., and Griffiths P. Statins and secondary prevention of coronary heart disease. Br J Community Nurs 9 (2004) 160-165
57. Pepine C.J. Optimizing lipid management in patients with acute coronary syndromes. Am J Cardiol 91 (2003) 30B-35B
58. Cleland J.G., Coletta A.P., Freemantle N., et al. Clinical trials update from the American College of Cardiology meeting. CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 7 (2005) 931-936
59. Ballantyne C.M. Current and future aims of lipid-lowering therapy. Changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 92 (2003) 3K-9K
60. Fonarow G.C., Wright R.S., Spencer F.A., et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96 (2005) 611-616
61. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
62. Krupski W.C., Layug E.L., Reilly L.M., et al., Study of Perioperative Ischemia (SPI) Research Group. Comparison of cardiac morbidity between aortic and infrainguinal operations. J Vasc Surg 15 (1992) 354-365
63. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. The United Kingdom Small Aneurysm Trial Participants. N Engl J Med 346 (2002) 1445-1452
64. Lindenauer P.K., Pekow P., Wang K., et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291 (2004) 2092-2099
65. Schouten O., Kertai M.D., Bax J.J., et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 95 (2005) 658-660
66. Biccard B.M., Sear J.W., and Foex P. The pharmacoeconomics of perioperative statin therapy. Anaesthesia 60 (2005) 1059-1063
67. Porter K.E., and Turner N.A. Statins for the prevention of vein graft stenosis. A role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 30 (2002) 120-126
68. Knatterud G.L., Rosenberg Y., Campeau L., et al., Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Circulation 102 (2000) 157-165
69. Christenson J.T. Preoperative lipid control with simvastatin reduces the risk for graft failure 1 year after myocardial revascularization. Cardiovasc Surg 9 (2001) 33-43
70. Nakamura K., Al-Ruzzeh S., Chester A.H., et al. Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries. Ann Thorac Surg 73 (2002) 1860-1865
71. Flaker G.C., Warnica J.W., Sacks F.M., et al., Cholesterol and Recurrent Events CARE Investigators. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol 34 (1999) 106-112
72. Mathew J.P., Grocott H.P., McCurdy J.R., et al. Preoperative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 19 (2005) 294-299
73. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
74. Palta S., Pai A.M., Gill K.S., et al. New insights into the progression of aortic stenosis. Implications for secondary prevention. Circulation 101 (2000) 2497-2502
75. Luo J.D., Zhang W.W., Zhang G.P., et al. Effects of simvastatin on left ventricular hypertrophy and function in rats with aortic stenosis. Zhongguo Yao Li Xue Bao 20 (1999) 345-348
76. Novaro G.M., Tiong I.Y., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
77. Shavelle D.M., Takasu J., Budoff M.J., et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
78. Wenke K. Management of hyperlipidaemia associated with heart transplantation. Drugs 64 (2004) 1053-1068
79. Mathis A.S., Dave N., Knipp G.T., et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61 (2004) 565-587
80. Imagawa D.K., Dawson III S., Holt C.D., et al. Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme: A reductase inhibitor pravastatin. Transplantation 62 (1996) 934-942
81. Johnson B.A., Iacono A.T., Zeevi A., et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 167 (2003) 1271-1278
82. O'Rourke B., Barbir M., Mitchell A.G., et al. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation. Results of a randomised double-blind placebo-controlled study. Int J Cardiol 94 (2004) 235-240
83. Wenke K., Meiser B., Thiery J., Nagel D., et al. Simvastatin initiated early after heart transplantation. 8-year prospective experience. Circulation 107 (2003) 93-97
84. See Jr. V.Y., DeNofrio D., Goldberg L., et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol 92 (2003) 11-15
85. Kato T., Tokoro T., Namii Y., et al. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc 32 (2000) 331-333
86. Weis M., Pehlivanli S., Meiser B.M., et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 38 (2001) 814-818
87. Taylor P.J., Kubler P.A., Lynch S.V., et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 38 (2004) 205-208
88. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation 70 (2000) SS51-SS57
89. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients. A multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
90. Cosio F.G., Pesavento T.E., Pelletier R.P., et al. Patient survival after renal transplantation III. The effects of statins. Am J Kidney Dis 40 (2002) 638-643
91. Prasad G.V., Ahmed A., Nash M.M., et al. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 63 (2003) 360-364
92. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 (2004) 956-965
93. Omar M.A., Wilson J.P., and Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35 (2001) 1096-1107
94. Rosenberg A.D., Neuwirth M.G., Kagen L.J., et al. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Analg 81 (1995) 1089-1091
95. Wilhelmi M., Winterhalter M., Fischer S., et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement. A possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 16 (2002) 471-475
96. Wright R.S., Murphy J.G., Bybee K.A., et al. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina. Efficacy and mechanism of benefit. Mayo Clin Proc 77 (2002) 1085-1092
97. Waters D., Schwartz G.G., and Olsson A.G. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial. A new frontier for statins?. Curr Control Trials Cardiovasc Med 2 (2001) 111-114
98. Chasman D.I., Posada D., Subrahmanyan L., et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
99. Kajinami K., Brousseau M.E., Ordovas J.M., et al. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175 (2004) 287-293
100. Heeschen C., Hamm C.W., Laufs U., et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105 (2002) 1446-1452
101. Eagle K.A., Guyton R.A., Davidoff R., et al., American College of Cardiology/American Heart Association. ACC/AHA guidelines for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34 (1999) 1262-1347
102. Khanderia U., Faulkner T.V., Townsend K.A., et al. Lipid-lowering therapy at hospital discharge after coronary artery bypass grafting. Am J Health Syst Pharm 59 (2002) 548-551
103. Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med 91 (1991) 18S-24S
104. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild-to-moderate cholesterol elevation (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80 (1997) 278-286